Abnormal cervical screening result in patients with indication for colposcopy with directed biopsy and endocervical curettage colposcopy with directed biopsy and endocervical curettage oral etoricoxib pain score
Conditions
Interventions
etoricoxib 90 mg, 30 mins prior to colposcopy, oral route,folic acid 5 mg, 30 mins prior to colposcopy, oral route
Active Comparator Drug,Placebo Comparator Drug
etoricoxib,placebo
Sponsors
None listed
Eligibility
Sex/Gender
Female
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: abnormal cervical screening result that indication for colposcopy according to ASCCP2019 1.ASC-US 2.ASC-H 3.AGC NOS 4.LSIL 5.HSIL 6.SCC 7.HPV16/18 infection
Exclusion criteria
Exclusion criteria: 1.NSAIDs allergy 2.pregnancy or breast feeding 3.history of pain killer 24 hours prior to colposcopy 4.contraindication for etoricoxib as below gastric ulcer or upper gastrointestinal bleeding severe hepatic disease (serum albumin <25ng/l) severe renal disease (CrCl <30 ml/min) inflammatory bowel disease heart failure blood pressure more than 140/90 mmHg coronary artery disease, peripheral arterial disease stroke history of thrombolytic drug, oral contraceptive pill
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pain score before colposcopy, speculum insertion, acetic acid apply, cervical biopsy, endocervical curettage, post colposcopy 10 mins, post colposcopy 24 hours Numerical rating scale | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse event after etoricoxib 30 mins - 24 hours Patient reported outcome using a questionnaire interview | — |
Countries
Thailand
Contacts
Public ContactSarunya Sivapornpan
Thammasat University hospital
Outcome results
None listed